Avalo Therapeutics (NASDAQ:AVTX) Price Target Cut to $10.00

Avalo Therapeutics (NASDAQ:AVTXGet Rating) had its target price cut by analysts at Oppenheimer to $10.00 in a note issued to investors on Tuesday, Stock Target Advisor reports. Oppenheimer’s price objective suggests a potential upside of 75.13% from the company’s current price.

Avalo Therapeutics Trading Down 1.6 %

Shares of Avalo Therapeutics stock opened at $5.71 on Tuesday. Avalo Therapeutics has a 12-month low of $2.42 and a 12-month high of $27.36. The company has a debt-to-equity ratio of 5.23, a current ratio of 1.07 and a quick ratio of 1.07. The company’s fifty day simple moving average is $4.93 and its two-hundred day simple moving average is $5.20.

Institutional Investors Weigh In On Avalo Therapeutics

A number of large investors have recently modified their holdings of the stock. Leo Brokerage LLC bought a new stake in Avalo Therapeutics during the first quarter worth about $45,000. Assenagon Asset Management S.A. bought a new stake in Avalo Therapeutics during the third quarter worth about $52,000. Renaissance Technologies LLC boosted its stake in Avalo Therapeutics by 819.1% during the first quarter. Renaissance Technologies LLC now owns 367,193 shares of the company’s stock worth $266,000 after acquiring an additional 327,241 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Avalo Therapeutics by 23.8% during the second quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company’s stock worth $324,000 after acquiring an additional 124,769 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in Avalo Therapeutics during the second quarter worth about $506,000.

About Avalo Therapeutics

(Get Rating)

Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.

See Also

Stock Target Advisor logo

Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.